Across TCGA pan-cancer cohorts, HIBCH Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HIBCH data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher HIBCH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HIBCH expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, COAD, and DLBC are the cancer types where HIBCH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
COAD	DFS	Median	All	0.218	0.692	.001	21	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.630	.031	4	view →
LUAD	OS	Median	All	0.277	0.787	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: HIBCH tumor-vs-normal RNA expression · all HIBCH data types